Akèy › Tit travay › Director, Regulatory Affairs

Director, Regulatory Affairs: Salè H-1B

40 aplikasyon kondisyon travay te itilize tit travay Director, Regulatory Affairs. Salè baz medyàn ofri $198,922; mwatye mitan $182,234–$219,258.

Demann (LCA)40

Salè medyan ofri$198,922

Mwatye salè yo$182,234–$219,258

10yèm–90yèm pousantaj$160,966–$226,410

Avoka imigrasyon, rekritè oswa anplwayè? Mete sèvis ou an tèt paj sa a — $99 pou 30 jou →

Anplwayè yo

Anplwayè	LCA	Salè medyan
AbbVie Inc.	3	$207,000
Rising Pharma Holdings Inc.	3	$190,443
Beam Therapeutics, Inc.	2	$211,500
Scilex Holding Company	2	$194,646
Teva Pharmaceuticals USA, Inc.	2	$193,116
AiCuris US Inc.	2	$215,000
International AIDS Vaccine Initiative (IAVI)	2	$166,860
Casper Pharma LLC.	2	$190,443
NC Transaction, Inc., dba News Corporation	1	$180,000
Aerovate Therapeutics, Inc.	1	$225,000
Wave Life Sciences USA, Inc.	1	$202,230
Leading Pharma, LLC	1	$140,000
Boston Scientific Corporation	1	$222,602
Mirum Pharmaceuticals, Inc.	1	$242,700
Innogenix Inc	1	$148,050
Allakos Inc.	1	$247,320
Shilpa Pharma Inc	1	$162,075
NC Transaction, Inc., dba NewsCorporation	1	$187,200
Annexon Biosciences, Inc.	1	$248,795
Institute of International Finance	1	$183,352
Mapp Biopharmaceutical, Inc.	1	$182,312
Curevo, Inc.	1	$239,096
T. Hasegawa USA, Inc.	1	$172,000
BeiGene USA, Inc.	1	$222,350
West Pharmaceutical Services, Inc.	1	$150,987
BioMarin Pharmaceutical Inc.	1	$206,190
Deciphera Pharmaceuticals, LLC	1	$220,000
Amneal Pharmaceuticals, LLC	1	$198,845
Teva Branded Pharmaceuticals Products R&D Inc.	1	$204,232
Dawn Scientific, Inc.	1	$130,000

Pa nivo salè

Nivo revni	Salè medyan
Nivo II (kalifye)	$178,360
Nivo III (eksperyans)	$190,443
Nivo IV (plen kompetans)	$213,005

Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.

Pa ane fiskal

Ane fiskal	LCA	Salè medyan
FY2023	11	$199,000
FY2024	6	$197,100
FY2025	14	$202,518
FY2026	9	$190,443

Vil yo

Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).